NKTR Earnings Date: Nov 12, 2026 (Estimated) — Nektar Therapeutics
NASDAQ · Healthcare · Biotechnology
Updated
When is NKTR's next earnings date?
Nektar Therapeutics (NKTR) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.07 on revenue of $10.3M.
How did NKTR do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Nektar Therapeutics posted EPS of -$1.23 versus the -$1.97 estimate, a beat of 39.7%. Revenue was $10.1M against a $10.4M estimate. The stock's 1-day post-earnings move was -3.8%.
How much does NKTR stock move after earnings?
NKTR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.1% (up or down) in the day after earnings.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -1.97 | -1.23 | +39.71% | $10.1M | ✅ Beat | -3.82% | -1.88% | -9.77% |
| 2026-05-07 | Q1 2026 | -1.53 | -1.82 | -18.95% | $10.9M | ❌ Miss | -1.78% | -10.84% | -32.09% |
| 2026-03-12 | Q4 2025 | -3.20 | -1.78 | +44.37% | $21.8M | ✅ Beat | +4.11% | +6.37% | +14.34% |
| 2025-11-06 | Q3 2025 | -2.81 | -1.87 | +33.45% | $11.8M | ✅ Beat | +1.54% | -2.12% | +3.92% |
| 2025-03-12 | Q4 2024 | -0.19 | -0.15 | +21.05% | $29.2M | ✅ Beat | -0.57% | +9.43% | -39.14% |
| 2024-11-07 | Q3 2024 | -0.21 | -0.18 | +14.29% | $24.1M | ✅ Beat | +2.19% | -14.60% | -26.28% |
| 2024-03-04 | Q4 2023 | -0.21 | -0.22 | -4.76% | $23.9M | ❌ Miss | -1.78% | -7.56% | +15.56% |
| 2023-11-07 | Q3 2023 | -0.20 | -0.19 | +5.00% | $24.1M | ✅ Beat | -8.76% | -6.93% | -7.41% |
Showing last 8 quarters.